EMA gives green light for 8 new medicines

EMA gives green light for 8 new medicines

The European Medicine Agency’s key
decision-making committee on human medicines (CHMP), has recommended eight
medicines for approval at its June meeting. 

The Committee recommended granting a conditional marketing authorisation for Abecma
(idecabtagene vicleucel) for the treatment of adult patients with relapsed and
refractory multiple myeloma who have received at least three previous
therapies, and whose cancer has worsened since receiving the last treatment.

The Committee adopted a positive opinion for Voxzogo (vosoritide)
for the treatment of achondroplasia in patients two years of age and above
whose epiphyses are not closed. Achondroplasia is a condition that impairs bone
growth and causes dwarfism.

Conditional marketing authorisation was recommended for Minjuvi (tafasitamab)
for the treatment of adult patients with relapsed or refractory diffuse large
B-cell lymphoma who are not eligible for autologous stem-cell transplant.

The Committee adopted a positive opinion, recommending the granting of
marketing authorisation for Bimzelx (bimekizumab)
for the treatment of moderate to severe plaque psoriasis.

Byooviz (ranibizumab) was given the green light for the treatment of neovascular
(wet) age-related macular degeneration, visual impairment due to diabetic
macular oedema, proliferative diabetic retinopathy, visual impairment due to macular
oedema secondary to retinal vein occlusion (branch RVO or central RVO), and
visual impairment due to choroidal neovascularisation.

Evrenzo (roxadustat) was granted a positive opinion for the treatment of anaemia
symptoms in patients with chronic kidney disease.

The CHMP recommended granting marketing authorisations for two generic medicinesAbiraterone Mylan (abiraterone
acetate) for the treatment of metastatic prostate cancer and Fingolimod
(fingolimod) for the treatment of relapsing-remitting multiple
sclerosis with high disease activity.

A total of 50 new medicines were approved in the EU in the first six
months of 2021, with a further 46 extensions of therapeutic indication.